

# **Therapy of Epilepsy**

**Yacoub Irshaid MD, PhD, ABCP**

**Department of Pharmacology**

# Therapy of Epilepsy

- There are **many types** of epilepsies characterized by different seizure types, with differences in severity and etiologies.
- In all epilepsies, there is **disrupted regulation of electrical activity in the brain resulting in synchronized and excessive neuronal discharge.**
- **Accurate classification and diagnosis** of seizure type, **including mode of seizure onset**, **is critical to selection of appropriate pharmacotherapy.**

# Therapy of Epilepsy


## Aims of Drug therapy:

- a) Reducing the frequency of seizures as much as possible.
- b) Minimizing adverse effects of antiseizure drugs.
- c) Addressing coexisting health and social conditions.
- d) Enhancing quality of life (QOL).

# Therapy of Epilepsy


- Some seizures are provoked by infections, fever (**febrile seizures**), drug overdose, **alcohol, barbiturate or benzodiazepine withdrawal**, brain hemorrhage, hypocalcemia, hypoglycemia, uremia, and eclampsia.
- **These seizures do NOT constitute epilepsy, they disappear once the provoking insult is removed or treated.**

## 2010 ILAE Revised Terminology for Classification of Seizures.



Source: J.T. DiPiro, R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, L.M. Posey: Pharmacotherapy: A Pathophysiologic Approach, 10th Edition, [www.accesspharmacy.com](http://www.accesspharmacy.com)  
Copyright © McGraw-Hill Education. All rights reserved.

# ILAE 2017 Classification of Seizure Types Expanded Version <sup>1</sup>



<sup>1</sup> Definitions, other seizure types and descriptors are listed in the accompanying paper and glossary of terms

<sup>2</sup> Degree of awareness usually is not specified

<sup>3</sup> Due to inadequate information or inability to place in other categories

# Therapy of Epilepsy

## Treatment:

- Anti-seizure drug (ASD) therapy is the mainstay of epilepsy treatment.
- ASDs provide symptomatic treatment only.
- They have NO disease modifying properties, and are NOT curative.
- Drugs act mainly to prevent seizures.
- Therapy is usually life-long.

# Therapy of Epilepsy

- The goal of ASD therapy should be to eliminate seizures with minimal adverse effects.
- In 20% to 35% of patients this may NOT be possible, and seizure control must be balanced with QOL goals.
- For those who can NOT obtain seizure freedom despite these therapies, a decrease in the number of seizures with minimized drug adverse effects will be a reasonable goal.



# Therapy of Epilepsy

If the therapeutic goal is NOT achieved with **monotherapy**:

1. Add a **second** antiseizure drug (ASD), with a different mechanism of action.
  2. Or switch to an **alternative single** ASD.
- **Emphasize treatment with a single drug.**

# Therapy of Epilepsy

- The drug treatment of first-choice depends on the type of epilepsy; and patient characteristics such as age, gender, co-morbid medical conditions, susceptibility to adverse effects, ability to comply with a prescribed regimen.
- Once the proper ASD is selected, patient education and understanding of the treatment plan is essential.

# Therapy of Epilepsy

- The single most common reason for treatment failure is medication non-adherence.
- Up to 60% of patients with epilepsy are non-adherent to therapy.

## Reasons for non-adherence:

- 1) Financial constraints.
- 2) Complexity of the drug regimen.
- 3) Frequent uncontrolled seizures.

# Therapy of Epilepsy

- **Anti-seizure drug withdrawal should be gradual, to avoid recurrence of seizures.** Sudden withdrawal can be associated with “**Status Epilepticus**”.
- Withdrawal seizures are more common with **benzodiazepines and barbiturates**, which should be withdrawn more slowly over a period of many months.

# Therapy of Epilepsy

## Pharmacologic Therapy:

- An ASD must be effective for the specific seizure type.
- Individualization of therapy is important.
- A patient may be better suited to receive one drug over the other, because of susceptibility for certain adverse effects or the presence of co-morbid conditions.

# Therapy of Epilepsy

- Patient characteristics such as age, gender, and medical conditions must be considered:
  1. Children may be more susceptible to **neuropsychiatric** adverse effects.
  2. Women of child-bearing potential should not receive **teratogenic** ASDs.
  3. The elderly may be more susceptible to adverse effects on **cognition**, therefore, avoid drugs that affect cognition.

# Therapy of Epilepsy

4. Patients with co-morbid conditions (migraine headache, tremor, or neuropathy) may benefit from the use of a drug that can also treat the other condition.
- **\*\* Extreme attention should be paid to drug-drug interactions with other drugs, and among ASDs themselves.**

# Therapy of Epilepsy

## Selection of ASDs:

1. Select one ASD, start with a low dose, and gradually titrate to a moderate dose goal, taking into account the patient's response to treatment.
  - If the patient is seizure free with NO adverse effects at a moderate therapeutic dose, then NO further increase in dose is necessary.
2. If there is NO adequate response at that dose, attempt increasing the dose.



# Therapy of Epilepsy

3. If the first ASD monotherapy is still ineffective, or if the patient experiences intolerable adverse effects, adding a second ASD with a different mechanism of action and **then** tapering and discontinuing the first ASD is appropriate.
4. If the second ASD is ineffective, combination therapy may be indicated (**although NOT desirable**).

# Therapy of Epilepsy

5. In elderly patients who are sensitive to falls, sedation, and neuro-cognitive adverse effects, start at much lower initial dose and then titrate slowly (weeks – months), with a lower maximum dose goal.
6. In patients with multiple recent seizures (higher frequency), a therapeutic dose needs to be reached much more quickly, and a more rapid titration over days instead of weeks is appropriate.

# Therapy of Epilepsy

## Effectiveness of ASDs:

- Some ASDs including carbamazepine, lamotrigine, ethosuximide, gabapentin, levetiracetam, oxcarbazepine, phenytoin, valproic acid, and zonisamide, have strong-enough evidence to be labeled as effective, or as probably effective as initial monotherapy in certain seizure types.
- Others have weaker evidence and can only be labeled as possibly or potentially effective.

# Therapy of Epilepsy

## Drug Resistance:

- Drug resistance is defined as: “failure of two tolerated and appropriately chosen ASD (as monotherapy or in combination) to achieve sustained seizure freedom.”
- Approximately 65% of patients can be maintained on one ASD and considered well controlled, although NOT necessarily seizure free.

# Therapy of Epilepsy

- The percentage of patients who are seizure-free on one drug after 12 months of treatment varies:
  - a) For only generalized tonic-clonic seizures (~ 50 %).
  - b) For only focal seizures (~ 25%).
  - c) For those with mixed seizure types (~ 25%).

# Therapy of Epilepsy

- Of the 35% of patients with unsatisfactory control on monotherapy, 10% will be well controlled with a two-drug combination.
- Of the remaining 25%, 20% will continue to have unsatisfactory control despite greater than two drug treatment and are considered drug-resistant.

# Pharmacokinetics and Drug-Drug Interactions

- Knowledge of ASD inducer or inhibitory effects on drug metabolizing enzymes is needed for the optimization of ASD therapy.
- Pharmacokinetic interactions are common and serious complicating factor in ASD selection.
- Inducers include: carbamazepine, lamotrigine, phenytoin, phenobarbital, vigabatrin.
- Inhibitors include: valproic acid, topiramate.

# Pharmacokinetics and Drug-Drug Interactions

- Caution should be experienced when any ASD is added to or withdrawn from a drug regimen.
- Knowledge of the presence of active metabolites of ASDs is important as they affect duration of action of the drug: carbamazepine, primidone.
- Drugs with toxic metabolites include valproic acid.



# Adverse Effects

**Some common adverse effects shared by ASDs:**

- 1. CNS adverse effects are among the most common effects of ASDs and include sedation, dizziness, blurred or double vision, difficulty in concentration, and ataxia.**
- 2. Impairment of cognition: barbiturates cause more cognitive impairment than any other ASDs.**
  - (in children barbiturates paradoxically cause hyperactivity).**

# Adverse Effects

- In general, newer agents have less effects on cognition. (except **topiramate** which causes substantial cognitive impairment).
- These effects can be avoided by titrating the dose upward very slowly, or can be improved by decreasing the dose.
- Patients switched from polytherapy to monotherapy may also demonstrate improvement in cognition.

# Adverse Effects

## 3. Osteomalacia and osteoporosis:

- Phenytoin, phenobarbital, carbamazepine, oxcarbazepine, ~~felbamate~~, and valproic acid, may **interfere with vitamin D metabolism and/or absorption.**
- **Patients receiving these drugs** should have:
  - a. Supplemental vitamin D and calcium.
  - b. Bone mineral density testing if other risk factors for osteoporosis are present.

# Role of Serum Concentration Monitoring

- **Monitoring of the older ASDs is used to optimize therapy for an individual patient, but NOT as a therapeutic end point in itself.**
- **The serum concentration result should be always interpreted in association with clinical response.**
- **Seizure control can occur before the “minimum” of the therapeutic range is achieved, and adverse effects can appear before the “maximum” of the range is achieved.**

# Role of Serum Concentration Monitoring

- Higher concentrations are needed to control focal dyscognitive seizures than to control tonic-clonic seizures.

**Serum levels can also be useful:**

- a. To document lack or loss of efficacy.
- b. To document non-adherence.
- c. To determine how much room there is to increase a dose based on expected toxicity.

# Role of Serum Concentration Monitoring

- d. In patients with significant renal or hepatic dysfunction.
- e. In those taking multiple drugs.
- f. In women who are pregnant or taking oral contraceptives.
- **Monitoring should be performed only at steady-state.**
- **Therapeutic concentration ranges have NOT been clearly defined for some of the second-generation ASDs.**

## Antiseizure Drugs Target Serum Concentration Ranges

<b>Drug</b>	<b>Target Concentration Range</b>
Phenobarbital	10 - 40 µg/mL
Clobazam	0.03 - 0.3 ng/mL
Clonazepam	20 - 70 ng/mL
Phenytoin	10 - 20 µg/mL
Ethosuximide	40 - 100 µg/mL
Carbamazepine	4 - 12 µg/mL
Gabapentin	2 - 20 µg/mL
Lamotrigine	4 - 20 µg/mL
Levetiracetam	12- 46 µg/mL
Tiagabine	0.02 - 0.2 µg/mL
Topiramate	5 - 20 µg/mL
Valproic acid	50 - 100 µg/mL
Vigabatrin	0.8 - 36 µg/mL
Zonisamide	10 - 40 µg/mL

## Antiseizure Drug Pharmacokinetic Data

ASD	Time to Steady-State (Days)	Active Metabolite	Protein binding (%)
<b>Carbamazepine</b>	21-28, for completion of autoinduction	10,11-epoxide	40-90
<b>Clobazam</b>	7-14	N-desmethyclobazam	80-90
<b>Eslicarbazepine</b>	4-5	Oxcarbazepine	
<b>Ethosuximide</b>	6-12	--	
<b>Ezogabine</b>	3-4	N-acetyl metabolite	80
<b>Felbamate</b>	5-7	--	
<b>Gabapentin</b>	1-2	--	
<b>Lacosamide</b>	3	--	
<b>Lamotrigine</b>	3-15	--	
<b>Levetiracetam</b>	2	--	
<b>Oxcarbazepine</b>	2	10-hydroxycarbazepine	
<b>Perampanel</b>	14-21	--	95
<b>Phenobarbital</b>	14-21	--	
<b>Phenytoin</b>	7-28	--	90
<b>Pregabalin</b>	1-2	--	
<b>Primidone</b>	1-4	Phenobarbital	
<b>Rufinamide</b>	2	--	
<b>Tiagabine</b>		--	95
<b>Topiramate</b>	4-5	--	
<b>Valproic acid</b>	1-3	toxic	90-95, Saturable
<b>Vigabatrin</b>		--	
<b>Zonisamide</b>	5-15	--	



# Evaluation of Therapeutic Outcomes

- 1. Clinical response is more important than the serum drug concentrations and involves:**
  - a. Identifying the type and number of seizures.**
  - b. Identifying drug adverse effects.**
- 2. Patients should record the severity and the frequency of seizures.**
- 3. Ascertain if the patient is truly seizure free.**

# Evaluation of Therapeutic Outcomes

4. **Monitor patient long-term for co-morbid conditions**, social adjustment (including Quality-Of-Life assessments), drug interactions, and adherence.
5. **Screen periodically for co-morbid neuropsychiatric disorders** (depression and anxiety).

# Personalized Pharmacotherapy

- The most important aspect of ASD use is individualization of therapy.
- The following should be considered together:
  1. Seizure type.
  2. Concomitant medical problems (hepatic function, renal function, psychiatric diseases, other neurologic problems, ...).
  3. Concurrent medications.
  4. Patient specific characteristics (age, gender, child-bearing ability, and ethnicity).

# Therapeutic Considerations in the Elderly

1. The elderly are often on polytherapy which may contribute to:
  - a. Increased sensitivity to neuro-cognitive effects.
  - b. Increased possibility of drug-drug interactions with ASDs that affect the cytochrome P450 (CYP450) system (carbamazepine, phenytoin, and valproic acid, ...).

# Therapeutic Considerations in the Elderly

2. Hypoalbuminemia is common in the elderly which may cause problems with highly bound ASD (phenytoin, valproic acid, ...).
3. The elderly experience body mass changes, such as an increase in fat to lean body mass or decrease in body water, which can affect the drug volume of distribution and elimination half-life.

# Therapeutic Considerations in the Elderly

4. The elderly may have **compromised renal or hepatic function** that require ASD dosage adjustment.
- **Lamotrigine** is considered the medication of choice in elderly, because it has equal efficacy to **carbamazepine** and **gabapentin**, and is better tolerated than carbamazepine.

# Therapeutic Considerations in the Young

- For neonates and infants, an increase in the total body water to fat ratio and a decrease in serum albumin and  $\alpha$ 1-acid glycoprotein can result in volume of distribution changes that affect ASD elimination half-life.
- Children up to the age of 3 years have decreased renal elimination of ASDs, especially in neonates.

# Therapeutic Considerations in the Young

- **Hepatic activity** is **reduced in neonates and infants**, but by **age 2 to 3 years it becomes more than that of adults**.
- Therefore, neonates and infants require **lower doses** of ASDs, while children require **higher doses** than adults (based on body weight).
- Therapeutic drug monitoring is especially important in the young (but the therapeutic blood levels range is NOT well-defined as in adults).



# Therapeutic Considerations in Women

- Some women develop “**catamenial seizures**” (just before and during the menstrual flow and at the time of ovulation), which **may be due to a slight increase of estrogen relative to progesterone, or due to progesterone withdrawal.**
- The risk is ~ 10 - 70% in women with epilepsy.
- Treatment: conventional ASDs are the **primary agents.**

# Therapeutic Considerations in Women

- At menopause, seizures improve in frequency, particularly the catamenial seizures.
- Enzyme-inducing ASDs increase the metabolism of estrogen, progesterone, and testosterone.
- They also increase production of sex hormone-binding globulin, leading to decreases in the free fraction of these hormones.
- All of this may lead to menstrual irregularity, infertility, sexual dysfunction, and polycystic ovary syndrome (PCOS).

# Therapeutic Considerations in Women

- Enzyme-inducing ASDs can cause **treatment failures in women taking oral contraceptives** due to increased metabolism of ethinyl estradiol (and progestin).
- **Valproic acid** may affect sex hormone concentrations causing hyper-androgenism and polycystic changes.

# Therapeutic Considerations in Men

- Men with epilepsy have **reduced fertility**.
- Carbamazepine, oxcarbazepine, and valproic acid are associated with **sperm abnormalities** in men.
- Valproic acid may cause **testicular atrophy** resulting in **reduced testosterone** levels.
- Various ASDs may affect **libido and sexual function in both men and women**.

# Clinical Considerations with Specific Drugs

## Carbamazepine:

### Mechanism of Action :

- It enhances fast inactivation of voltage-gated Na<sup>+</sup> channels.

### Place in Therapy:

- It is considered **first-line** in many seizure types: **focal** onset seizures, **generalized tonic-clonic seizures**, and **mixed seizure** types.

# Clinical Considerations with Specific Drugs

- It may worsen absence seizures, and precipitate tonic-clonic seizures in patients with other generalized seizure types.

## Drug Interactions:

1. Carbamazepine **induces** the metabolism of primidone, phenytoin, ethosuximide, valproic acid, and clonazepam.
2. Phenytoin and phenobarbital **decrease** steady-state concentration of carbamazepine by enzyme **induction**.

# Clinical Considerations with Specific Drugs

3. Propoxyphene, troleandomycin, and valproic acid may **inhibit** carbamazepine clearance and **increase** its steady-state levels.
4. CYP3A4 inhibitors may potentially increase carbamazepine serum concentrations.

## Important Adverse Reactions:

### A. Concentration-dependent:

- Diplopia, dizziness, unsteadiness, drowsiness, nausea.

# Clinical Considerations with Specific Drugs

## **B. Idiosyncratic:**

- **Blood dyscrasias, Steven-Johnson syndrome or toxic epidermal necrolysis.**

## **C. Chronic:**

- **Hyponatremia, metabolic bone disease (monitor serum calcium and vitamin D).**



# Clinical Considerations with Specific Drugs

## Phenytoin:

### Mechanism of Action:

- It inhibits voltage-gated Na<sup>+</sup> channels.

### Place in Therapy:

- Phenytoin is used for **focal onset seizures and generalized tonic-clonic seizures.**
- At very high concentrations of greater than 50 µg/mL, **it can exacerbate seizures.**

# Clinical Considerations with Specific Drugs

## Pharmacokinetics:


- The oral absorption of phenytoin may be saturable at doses above 400 mg/day.
- Phenytoin is highly protein bound, and it is essential to know the patient's serum albumin level when interpreting serum phenytoin concentrations.
- Significant renal dysfunction will also alter phenytoin protein binding.
- It distributes to breast milk and it crosses the placenta.

# Clinical Considerations with Specific Drugs

- Phenytoin displays Michaelis–Menten pharmacokinetics, (or zero-order kinetics).

The metabolism of phenytoin saturates at doses used clinically, so that a small change in dose can result in a disproportionately large increase in serum concentrations, potentially leading to toxicity.

# Clinical Considerations with Specific Drugs



**FIGURE 24-5** Nonlinear relationship of phenytoin dosage and plasma concentrations. Five patients (identified by different symbols) received increasing dosages of phenytoin by mouth, and the steady-state serum concentration was measured at each dosage. The curves are not linear, since, as the dosage increases, the metabolism is saturable. Note also the marked variation among patients in the serum levels achieved at any dosage. (Modified, with permission, from Jusko WJ: Bioavailability and disposition kinetics of phenytoin in man. In: Kellaway P, Peterson I [editors]: *Quantitative Analytic Studies in Epilepsy*. Raven Press, 1977.)

# Clinical Considerations with Specific Drugs

## Drug Interactions:

1. Phenytoin is an **inducer** of both CYP450 and UGT isozymes (which conjugate drugs with glucuronic acid).
2. It decreases folic acid absorption.
  - Folic acid replacement can reduce phenytoin concentration and result in loss of efficacy.
3. Phenylbutazone and sulfonamides can **displace** phenytoin from binding sites to plasma proteins.

# Clinical Considerations with Specific Drugs

- **Hypoalbuminemia** results in decreased total plasma drug concentration but **NOT** necessarily the free concentration.
  - In these 2 cases intoxication may occur if total drug levels are increased by increasing the dose.
4. Phenobarbital and carbamazepine induce the metabolism of phenytoin.
  5. Isoniazid inhibits the metabolism of phenytoin.

# Clinical Considerations with Specific Drugs

## Important Adverse Reactions:

### A. Concentration-dependent:

- Diplopia, blurring of vision, nystagmus, ataxia, dizziness, somnolence, incoordination, sedation, behavioral changes, cognitive impairment, fatigue.

### B. Idiosyncratic:

- Blood dyscrasias, Steven-Johnson syndrome or toxic epidermal necrolysis, **pseudolymphoma**.

### C. Chronic:

- Cerebellar syndrome, connective tissue changes, skin thickening, folate deficiency, gingival hyperplasia, hirsutism, coarsening of facial features, acne, metabolic bone disease (monitor serum calcium and vitamin D).

# Clinical Considerations with Specific Drugs

## Valproic Acid:

### Mechanism of Action:

- It may potentiate postsynaptic GABA responses.

### Place in Therapy:

- Valproic acid is **first-line therapy for generalized seizures, including myoclonic, atonic, and absence seizures.**
- It is also used in **migraine headache and bipolar disorders.**



# Clinical Considerations with Specific Drugs

## Pharmacokinetics:

- Valproic acid is **extensively bound to albumin, and binding is saturable at high concentrations, or in patients with hypoalbuminemia.**
- The primary pathway of valproic acid metabolism is  $\beta$ -oxidation, then glucuronidation.
- **One of its metabolites (4-ene-VPA) may be increased with enzyme-inducing drugs, and may cause hepatotoxicity.**
- **It crosses into the placenta and attains high concentrations in fetal circulation (Teratogenic).**

# Clinical Considerations with Specific Drugs

## Drug Interactions:

1. Highly protein-bound drugs (free fatty acids, phenytoin, aspirin) can displace valproic acid.
2. It displaces phenytoin from plasma proteins.
3. It can inhibit specific CYP450 isozymes, epoxide hydrolase, and UGT isozymes.
4. It inhibits the metabolism of phenobarbital, phenytoin, carbamazepine, lamotrigine and other drugs.

# **Clinical Considerations with Specific Drugs**

- 5. Oral contraceptives may increase the clearance of valproic acid and lower serum levels by 20%.**
- 6. Meropenem can lower valproic acid levels.**

# Clinical Considerations with Specific Drugs

## Important Adverse Reactions:

### A. Concentration-dependent:

- GI upset, sedation, unsteadiness, tremor, thrombocytopenia.

### B. Idiosyncratic:

- Acute hepatic failure, acute pancreatitis, alopecia.

### C. Chronic:

- Polycystic ovary syndrome, weight gain, menstrual cycle irregularities, hyperammonemia.

# Clinical Considerations with Specific Drugs

## Ethosuximide:

### Mechanism of Action:

- Inhibition of T-type  $\text{Ca}^{2+}$  channels.

### Place in Therapy:

- It is a first-line treatment for absence seizures. It has a very narrow spectrum of activity.

### Drug Interactions:

- Valproic acid may inhibit ethosuximide's metabolism, when the metabolism of ethosuximide is near saturation.

# Clinical Considerations with Specific Drugs

## Important Adverse Reactions:

### A. Concentration-dependent:

- Ataxia, drowsiness, GI upset, unsteadiness, hiccoughs.

### B. Idiosyncratic:

- Blood dyscrasia, rash.

### C. Chronic:

- Behavioral changes, headache.

# Clinical Considerations with Specific Drugs

## Lamotrigine:

### Mechanism of Action:

- Lamotrigine inhibits voltage-gated Na<sup>+</sup> channels.
- It modulates high voltage-gated Ca<sup>2+</sup> channels.
- It modulates hyperpolarization-activated cation channels.
- It attenuates release of glutamate and to a lesser extent, GABA and dopamine.

# Clinical Considerations with Specific Drugs

## Place in Therapy:

1. Monotherapy and adjunctive treatment in patients with focal onset seizures, as a first- or second-line therapy.
  2. It is used in primary generalized tonic-clonic seizures and for primary generalized seizures of Lennox-Gastaut Syndrome (LGS).
- Its half-life is prolonged in renal failure, and is dialyzable.



# Clinical Considerations with Specific Drugs

## Drug Interactions:

- Valproic acid inhibits its metabolism.
- Carbamazepine increased its CNS adverse effects.
- Oral contraceptives reduce its serum concentrations because of induction of glucuronidation by ethinyl estradiol.

# Clinical Considerations with Specific Drugs

## Important Adverse Reactions:

### A. Concentration-dependent:

- Diplopia, dizziness, unsteadiness, headache.

### B. Idiosyncratic:

- Generalized erythematous and morbilliform rash, Steven-Johnson syndrome, which may necessitate withdrawal.

# Clinical Considerations with Specific Drugs

## Topiramate

### Mechanism of Action:

- It has multiple modes of action involving voltage-dependent  $\text{Na}^+$  channels,  $\text{GABA}_A$ -receptor subunits, high-voltage  $\text{Ca}^{2+}$  channels, and kainate/ $\alpha$ -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) subunits.
- It also **inhibits carbonic anhydrase**, which may have some antiseizure effects.

# Clinical Considerations with Specific Drugs

## Place in Therapy:

- It is used as monotherapy or adjunctive therapy for **focal onset seizures** in patients 2 years or older.
- It is also used for **tonic–clonic seizures** in primary generalized epilepsy and generalized seizures in patients with LGS.
- It has benefit in patients with co-morbidities (**migraines, obesity**).

# Clinical Considerations with Specific Drugs

## Drug Interactions:

- It increases phenytoin serum concentrations due to inhibition of CYP2C19.
- It may increase the clearance of valproic acid and the formation of its toxic metabolites.
- It increases the clearance of ethinyl estradiol at doses higher than 200 mg/day.
- Dose should be adjusted in renal impairment.
- Metabolism is increased 50% when given with enzyme-inducing ASDs.

# Clinical Considerations with Specific Drugs

## Important Adverse Reactions:

### A. Concentration-dependent:

- Difficulty concentrating, psychomotor slowing, speech or language problems, somnolence, fatigue, dizziness, headache.

### B. Idiosyncratic:

- Metabolic acidosis, acute glaucoma, oligohydrosis (deficient sweating).

### C. Chronic:

- Kidney stones, weight loss.

# Clinical Considerations with Specific Drugs

## Gabapentin:

### Mechanism of Action:

- It elevates human brain GABA levels.
- It binds to the  $\alpha 2\delta$  subunit of  $\text{Ca}^{2+}$  channels which may explain its analgesic effects.

### Place in Therapy:

- It is used for **focal-onset seizures** with or without secondary generalization in patients **3 years and older**.
- It is useful in treating **epilepsies with neuropathic pain**.

# Clinical Considerations with Specific Drugs

## Drug Interactions:

- ~~Cimetidine reduce clearance by 10%.~~
- Bioavailability is reduced 20% by aluminum antacids.

## Important Adverse Effects:

### A. Concentration-dependent:

- Dizziness, somnolence, fatigue, ataxia.

### B. Idiosyncratic:

- Pedal edema

### D. Chronic:

- Weight gain.



# Clinical Considerations with Specific Drugs

## Levetiracetam:

### Mechanism of Action:

- It binds to synaptic vesicle protein SV2A, in presynaptic terminals and inhibits neurotransmitter release.

### Place in Therapy:

- **Adjunctive therapy** in **focal-onset seizures** in patients 12 years of age or older, **myoclonic seizures**, and **primary generalized seizures.**

# Clinical Considerations with Specific Drugs

## Pharmacokinetics:

- **Renal elimination mainly (66%).**
- Dose should be reduced by 50% in severe liver cirrhosis.
- It is **significantly excreted into breast milk.**

## Important Adverse Effects:

### A. Concentration-dependent:

- Sedation, behavioral disturbances.

### B. Idiosyncratic:

- Psychosis.

# Clinical Considerations with Specific Drugs

## Zonisamide:

### Mechanism of Action:

- It inhibits slow Na<sup>+</sup> channels and T-type Ca<sup>2+</sup> channels , and possibly glutamate release.
- It has a weak carbonic anhydrase inhibitory effect.

### Place in Therapy:

- It is used for the **adjunctive treatment of focal-onset seizures** and may be considered first-line.

### Pharmacokinetics:

- It crosses the placenta, and the concentration in breast milk is similar to that in the plasma.

# Clinical Considerations with Specific Drugs

## Important Adverse Effects:

### A. Concentration-dependent:

- Dizziness, sedation, cognitive impairment, nausea.

### B. Idiosyncratic:

- Rash, metabolic acidosis, oligohydrosis

### D. Chronic:

- Kidney stones, weight loss.